Sculptra Butt Lift: What the Label, the Studies and the FDA Reports Show About Sculptra on the Buttocks

"Sculptra butt lift", "Sculptra BBL" and "Sculptra for hip dips" are sold on clinic pages across the US, often with a vial count and a price. Most of those pages say what the treatment will do. This page sets out what is on the public record instead: what FDA has approved Sculptra for, what the published studies of poly-L-lactic acid on the buttocks tested and how many vials they used, and what has been reported to FDA. It was checked on 6 October 2026. It is not a treatment recommendation and says nothing about who should have it. That is a decision for a qualified clinician.

What the US label covers — and what it does not

Sculptra is injectable poly-L-lactic acid (PLLA), regulated as a device under premarket approval P030050. Our Sculptra explainer sets out its approval history in full. The point that matters here is short: every approved use is on the face — facial fat loss in people with HIV (2004), nasolabial folds and other facial wrinkles (2009), and fine lines and wrinkles of the cheek (2023).

FDA's approval database, read on 6 October 2026, held 55 records under P030050, the newest a September 2026 manufacturing change. A search of every record's approval statement for "buttock", "gluteal", "body", "cellulite" or "thigh" returned none. So buttock and hip treatment is off-label: a licensed clinician may legally use an approved device this way, but the use was not part of what FDA reviewed for safety and effectiveness. The manufacturer's evaluations in several adverse-event reports to FDA say the same thing in plain words, describing Sculptra as "used off label to buttocks".

What has been published on PLLA in the buttocks and hips

A PubMed search on 6 October 2026 for poly-L-lactic acid (or PLLA, or Sculptra) together with the buttocks, gluteal region, hips or cellulite, and with injection or filler, returned 22 records. None was retracted. Read one by one, they sort into a small set of trials, a few case series, and a larger set of reviews and expert opinion:

What the table shows:

• Three randomized trials exist, and they are small — 15, 20 and 31 women. Only one of them, SPLASH, measured volume in the hip area, which is what a "butt lift" is sold on. The other two measured cellulite, and in one of them every participant also had subcision, a separate procedure that cuts the bands behind cellulite dimples, so the PLLA's own contribution cannot be fully separated.
• SPLASH reported a measurable change. On ultrasound, the treated side's dermis and fat layers thickened by 26.1% and 27%, the saline side did not change, and blinded investigators rated the treated hip dips as improved. Fifteen women, one site, nine months.
• The buttock-volume evidence is retrospective. The two studies of buttock augmentation itself — 60 and 51 patients — are look-backs at clinic records with photograph assessment and no control group, and one of them used a different PLLA product.
• The rest is expert opinion. Consensus and recommendation papers on PLLA for the buttocks and body (Harper 2022 among them) describe practice; they do not add trial data.

Vial counts, as the studies report them

The question clinics and readers ask most is how many vials are used. The published record gives numbers, but not a standard, and they come from different designs:

Two things are worth noticing. The 2020 paper says outright that the vial count was set by budget, not by a protocol — so its "20 vials" conclusion describes the patients who could pay for that many. And the body-use papers mix Sculptra with a lot more water than the face label describes (the pivotal cheek trial reconstituted a vial in 8 mL; the 2026 chart review mostly used 10 to 15 mL or more). That is a different preparation from the one FDA reviewed. None of these figures is a recommendation; how much is used for any person is a clinician's decision.

What has been reported to FDA

FDA's MAUDE database collects reports of problems with medical devices. On 6 October 2026 it held 2,023 reports naming Sculptra (data last updated 29 September 2026). Of these, 19 contain text mentioning the buttocks, gluteal region or "butt". Read one by one:

By year received, five of the 19 arrived in 2026 alone. Two of the 2026 events were each filed twice, once by each of two reporting companies, so 19 reports are fewer than 19 patients. Two of the 19 are consumer complaints rather than injuries — one about an out-of-date vial, one about paying for ten vials with no visible result. The manufacturer's assessments in recent reports describe the use as off-label, and one 2026 report of sepsis after a "BBL" with Sculptra states the product had been hyper-diluted and "intentionally misused with regard to reconstitution".

A device report proves neither that the device caused the event nor how often such events happen; reporting is voluntary for patients and clinicians. What these 19 do show is the kind of event that reaches FDA from buttock use: infection and nodules dominate, which is different from the facial reports, where swelling leads.

Why it is sold against the surgical BBL

"Sculptra BBL" borrows the name of the Brazilian butt lift, the surgical transfer of a patient's own fat into the buttocks. That procedure has a documented mortality problem. A task force of the Aesthetic Surgery Education and Research Foundation surveyed plastic surgeons in 2017: 692 surgeons reporting 198,857 gluteal fat-grafting cases recorded 32 deaths from pulmonary fat embolism and 103 non-fatal fat emboli over their careers, with the risk concentrated where fat was injected into the deep muscle (Mofid 2017).

That record is the marketing backdrop: an injectable with no fat transfer and no surgery is presented as the safer route. But the two are not compared in any published trial. The PLLA studies above are small and short, the surgical figure is a survey of surgeons' recall, and the two procedures do different things — one moves fat, the other relies on a tissue response to an implant. A comparison of outcomes between them is not something the record supports.

What is and is not established

Established: Sculptra is approved only for the face; buttock and hip use is off-label; three small randomized trials of PLLA in this area exist, one on hip volume and two on cellulite; published series report mostly minor injection-site effects; FDA's device-report database holds 19 buttock-related reports, most of them infections or nodules; vial counts in the literature range from 2 per area to a total of 20 or more and are not standardised.

Not established: how long a buttock result lasts beyond two years in anyone; how a "Sculptra BBL" compares with surgical fat grafting on safety or outcome; how often serious complications occur in buttock use; or what the right dilution and dose are — the body-use papers use preparations the face label does not describe. Anyone weighing this treatment is best served by a board-certified clinician who can explain the off-label status, the evidence above and their own complication data.

Sources

• US FDA, Premarket Approval database via openFDA device/pma (pma_number:P030050), queried 2026-10-06, data last updated 2026-09-28: 55 records, approval statements searched for buttock/gluteal/body/cellulite/thigh (0).
• US FDA, MAUDE via openFDA device/event (device.brand_name:sculptra, 2,023 reports; with mdr_text.text:(buttock OR buttocks OR gluteal OR butt), 19 reports, each read), queried 2026-10-06, data last updated 2026-09-29.
• Zubair R, Ishii L, Loyal J, Hartman N, Fabi SG. SPLASH: split-body randomized clinical trial of poly-L-lactic acid for adipogenesis and volumization of the hip dell. Dermatol Surg 2024;50(12):1155-62. PMID 39503574.
• Almukhtar RM, Wood ES, Loyal J, Hartman N, Fabi SG. A randomized, single-center, double-blinded, split-body clinical trial of poly-L-lactic acid for the treatment of cellulite of the buttocks and thighs. Dermatol Surg 2023;49(4):378-82. PMID 36826378.
• Swearingen A, Medrano K, Ferzli G, Sadick N, Arruda S. Randomized, double-blind, placebo-controlled study of poly-L-lactic acid for treatment of cellulite in the lower extremities. J Drugs Dermatol 2021;20(5):529-33. PMID 33938690.
• Durairaj KK, Devgan L, Lee A, et al. Poly-L-lactic acid for gluteal augmentation found to be safe and effective in retrospective clinical review of 60 patients. Dermatol Surg 2020;46 Suppl 1:S46-53. PMID 32976171.
• Durairaj KK, Vafa A, Aguilera SB, et al. Nonfacial use of injectable poly-L-lactic acid: safety data from a multicenter observational study in the United States. Aesthet Surg J Open Forum 2026;8:ojag053. PMID 42004285.
• Russo PR, Bovani B, De Angelis F, et al. Multicentric retrospective study on safety and efficacy of a novel injectable poly-L-lactic acid for buttocks recontouring. J Cosmet Dermatol 2025;24(1):e16580. PMID 39445541.
• Harper J, Avelar L, Haddad A, et al. Expert recommendations on the use of injectable poly-L-lactic acid for contour deficiencies of the buttocks. J Drugs Dermatol 2022;21(1):21-6. PMID 35005870.
• Mofid MM, Teitelbaum S, Suissa D, et al. Report on mortality from gluteal fat grafting: recommendations from the ASERF Task Force. Aesthet Surg J 2017;37(7):796-806. PMID 28369293.
• PubMed E-utilities search, 2026-10-06: ("poly-L-lactic acid"[tiab] OR "poly-l-lactic"[tiab] OR PLLA[tiab] OR sculptra[tiab]) AND (buttock*[tiab] OR gluteal[tiab] OR cellulite[tiab] OR hip[tiab]) AND (inject*[tiab] OR filler*[tiab]) — 22 records, each read; with Retracted Publication[pt] — 0. Broader set without the injection term: 45.